

20<sup>th</sup> May, 2025

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub.: Presentation to analysts on Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2025**

The presentation on Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2025 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI  
COMPANY SECRETARY

Encl : A/a

---

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg.Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,  
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com



## Q4 FY 2024-25

Revenues: Summary



# Revenue: Summary

Revenues (Rs cr)	Q4 FY25	Q4 FY24	Gr%
India	1,545	1,380	12%
United States	302	262	15%
Germany	286	280	2%
Brazil	351	372	-6%
Others	475	451	5%
<b>Total</b>	<b>2,959</b>	<b>2,745</b>	<b>8%</b>



# Revenue: Summary

Revenues (Rs cr)	FY25	FY24	Gr%
India	6,393	5,666	13%
United States	1,100	1,078	2%
Germany	1,139	1,074	6%
Brazil	1,100	1,126	-2%
Others	1,784	1,784	0%
<b>Total</b>	<b>11,516</b>	<b>10,728</b>	<b>7%</b>

